{'fraction_non_alphanumeric': 0.05946481665014866, 'fraction_numerical': 0.030723488602576808, 'mean_word_length': 5.0843373493975905, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical and prognostic heterogeneity of C and D GOLD groups

“High risk” groups for exacerbations of chronic obstructive pulmonary disease (COPD) in the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) proposal (i.e. groups C and D) [1] include: patients with a forced expiratory volume in 1 s FEV1 <50% reference and <2 exacerbations year-1 (subgroups C1 and D1); patients with ≥2 exacerbations·year-1 and an FEV1 ≥50% reference (subgroups C2 and D2); and patients with both FEV1 <50% ref. and ≥2 exacerbations·year-1 (subgroups C3 and D3) [2–5]. We hypothesised that these high-risk subgroups will differ in other clinical, functional and biological characteristics and will be associated with different long-term outcomes. We explored this hypothesis in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) cohort [6, 7]. The results of this study show that “high-risk” COPD patients (GOLD groups C and D) are highly heterogeneous http://ow.ly/LTMOv